Sigilon Therapeutics

Canaccord Genuity Acted as a Bookrunner in an Initial Public Offering for Sigilon Therapeutics, Inc.

Transaction Overview:

Sigilon Therapeutics, Inc. (the “Company”) (Nasdaq:SGTX), priced its $126 million upsized initial public offering on December 3, 2020 at a price of $18 per share. The Company issued 7,000,000 shares of common stock. The Underwriters exercised their option to purchase an additional $1,050,000 shares of common stock at the initial public offering price, bringing the total proceeds to $144.9 million, less the underwriting discounts and commissions.

Company Overview:
​​​​​​​
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis.